Germany · Delayed Price · Currency is EUR Elicera Therapeutics AB Statistics
Total Valuation
FRA:8E8 has a market cap or net worth of EUR 28.92 million. The enterprise value is 25.74 million.
| Market Cap | 28.92M |
| Enterprise Value | 25.74M |
Important Dates
The next estimated earnings date is Friday, February 13, 2026.
| Earnings Date | Feb 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 48.54M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +52.64% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 51.88% |
| Owned by Institutions (%) | 16.61% |
| Float | 20.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 23.34 |
| PB Ratio | 10.54 |
| P/TBV Ratio | 10.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -21.81 |
| EV / Sales | 20.63 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.35
| Current Ratio | 5.35 |
| Quick Ratio | 5.35 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,122.62 |
Financial Efficiency
Return on equity (ROE) is -48.58% and return on invested capital (ROIC) is -31.95%.
| Return on Equity (ROE) | -48.58% |
| Return on Assets (ROA) | -25.08% |
| Return on Invested Capital (ROIC) | -31.95% |
| Return on Capital Employed (ROCE) | -45.26% |
| Revenue Per Employee | 619,412 |
| Profits Per Employee | -589,949 |
| Employee Count | 2 |
| Asset Turnover | 0.40 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +258.36% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +258.36% |
| 50-Day Moving Average | 0.52 |
| 200-Day Moving Average | 0.44 |
| Relative Strength Index (RSI) | 44.51 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:8E8 had revenue of EUR 1.24 million and -1.18 million in losses. Loss per share was -0.03.
| Revenue | 1.24M |
| Gross Profit | 1.24M |
| Operating Income | -1.24M |
| Pretax Income | -1.18M |
| Net Income | -1.18M |
| EBITDA | -1.24M |
| EBIT | -1.24M |
| Loss Per Share | -0.03 |
Balance Sheet
The company has 3.16 million in cash and n/a in debt, giving a net cash position of 3.16 million.
| Cash & Cash Equivalents | 3.16M |
| Total Debt | n/a |
| Net Cash | 3.16M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 2.74M |
| Book Value Per Share | 0.06 |
| Working Capital | 2.74M |
Cash Flow
| Operating Cash Flow | -1.42M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of -100.23% and -95.24%.
| Gross Margin | 100.00% |
| Operating Margin | -100.23% |
| Pretax Margin | -95.24% |
| Profit Margin | -95.24% |
| EBITDA Margin | -100.14% |
| EBIT Margin | -100.23% |
| FCF Margin | n/a |
Dividends & Yields
FRA:8E8 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -52.64% |
| Shareholder Yield | -52.64% |
| Earnings Yield | -4.08% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:8E8 has an Altman Z-Score of 11.76 and a Piotroski F-Score of 2.
| Altman Z-Score | 11.76 |
| Piotroski F-Score | 2 |